LILRB1 Antibody

中文名稱：

LILRB1兔多克隆抗體
貨號：

CSB-PA847747LA01HU
規(guī)格：

￥440
圖片：
Western Blot
Positive WB detected in: THP-1 whole cell lysate, Rat brain tissue
All lanes: LILRB1 antibody at 3.5µg/ml
Secondary
Goat polyclonal to rabbit IgG at 1/50000 dilution
Predicted band size: 71, 72, 50 kDa
Observed band size: 71 kDa

IHC image of CSB-PA847747LA01HU diluted at 1:400 and staining in paraffin-embedded human tonsil tissue performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a biotinylated secondary antibody and visualized using an HRP conjugated SP system.

Immunofluorescence staining of 293 cells with CSB-PA847747LA01HU at 1:133, counter-stained with DAPI. The cells were fixed in 4% formaldehyde, permeabilized using 0.2% Triton X-100 and blocked in 10% normal Goat Serum. The cells were then incubated with the antibody overnight at 4°C. The secondary antibody was Alexa Fluor 488-congugated AffiniPure Goat Anti-Rabbit IgG(H+L).
其他：

產(chǎn)品詳情
產(chǎn)品評價
相關(guān)產(chǎn)品
靶點詳情

產(chǎn)品詳情

產(chǎn)品名稱：

Rabbit anti-Homo sapiens (Human) LILRB1 Polyclonal antibody
Uniprot No.：

Q8NHL6
基因名：

LILRB1
別名：

CD85 antibody; CD85 antigen antibody; CD85 antigen like family member J antibody; CD85 antigen-like family member J antibody; CD85j antibody; CD85j antigen antibody; Ig like transcript 2 antibody; ILT 2 antibody; ILT-2 antibody; ILT2 antibody; immunoglobulin like transcript 2 antibody; Immunoglobulin-like transcript 2 antibody; leukocyte Ig like receptor 1 antibody; Leukocyte immunoglobulin like receptor 1 antibody; leukocyte immunoglobulin like receptor subfamily B member 1 antibody; Leukocyte immunoglobulin like receptor subfamily B member 1 precursor antibody; leukocyte immunoglobulin like receptor subfamily B member 1 soluble isoform antibody; leukocyte immunoglobulin like receptor, subfamily B, member 1 antibody; Leukocyte immunoglobulin-like receptor 1 antibody; Leukocyte immunoglobulin-like receptor subfamily B member 1 antibody; leukocyte immunoglobulin-like receptor subfamily B member 1 soluble isoform antibody; leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 1 antibody; LILRB1 antibody; LIR 1 antibody; LIR-1 antibody; LIR1 antibody; LIRB1_HUMAN antibody; MIR 7 antibody; MIR-7 antibody; MIR7 antibody; Monocyte/macrophage immunoglobulin like receptor 7 antibody; Monocyte/macrophage immunoglobulin-like receptor 7 antibody; PIR B antibody; PIRB antibody
宿主：

Rabbit
反應(yīng)種屬：

Human, Rat
免疫原：

Recombinant Human Leukocyte immunoglobulin-like receptor subfamily B member 1 protein (483-650AA)
免疫原種屬：

Homo sapiens (Human)

標記方式：

Non-conjugated

本頁面中的產(chǎn)品，LILRB1 Antibody (CSB-PA847747LA01HU)，的標記方式是Non-conjugated。對于LILRB1 Antibody，我們還提供其他標記。見下表：

標記方式	貨號	產(chǎn)品名稱	應(yīng)用
HRP	CSB-PA847747LB01HU	LILRB1 Antibody, HRP conjugated	ELISA
FITC	CSB-PA847747LC01HU	LILRB1 Antibody, FITC conjugated
Biotin	CSB-PA847747LD01HU	LILRB1 Antibody, Biotin conjugated	ELISA

克隆類型：

Polyclonal
抗體亞型：

IgG
純化方式：

>95%, Protein G purified
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
產(chǎn)品提供形式：

Liquid
應(yīng)用范圍：

ELISA, WB, IHC, IF

推薦稀釋比：

Application	Recommended Dilution
WB	1:500-1:5000
IHC	1:200-1:500
IF	1:50-1:200

Protocols：

ELISA Protocol
Western Blotting (WB) Protocol
Immunohistochemistry (IHC) Protocol
Immunofluorescence (IF) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產(chǎn)品評價

靶點詳情

功能：

Receptor for class I MHC antigens. Recognizes a broad spectrum of HLA-A, HLA-B, HLA-C, HLA-G and HLA-F alleles. Receptor for H301/UL18, a human cytomegalovirus class I MHC homolog. Ligand binding results in inhibitory signals and down-regulation of the immune response. Engagement of LILRB1 present on natural killer cells or T-cells by class I MHC molecules protects the target cells from lysis. Interaction with HLA-B or HLA-E leads to inhibition of FCER1A signaling and serotonin release. Inhibits FCGR1A-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions. Recognizes HLA-G in complex with B2M/beta-2 microglobulin and a nonamer self-peptide. Upon interaction with peptide-bound HLA-G-B2M complex, triggers secretion of growth-promoting factors by decidual NK cells. Reprograms B cells toward an immune suppressive phenotype.
基因功能參考文獻：
1. single nucleotide polymorphism is associated with increased carotid intimal media thickness in renal transplant recipients PMID: 28987961
2. MAFG is a direct target gene of miRNA-7.The direct regulation of MAFG through miR-7 and their involvement in the development of cisplatin resistance in human tumor cells. PMID: 29158814
3. Results show that LILRB1 rs41308748:AA predisposed to the endometriosis and its progression. PMID: 29234882
4. results suggest that P. falciparum has acquired multiple RIFINs to evade the host immune system by targeting immune inhibitory receptors, as LAIR1 and LILRB1 PMID: 29186116
5. The exosomes-containing miR-7-5p is a crucial mediator of bystander autophagy. PMID: 27417393
6. we confirmed that the RASSF2-PAR-4 axis was mainly responsible for miR-7 functions in CAFs using bioinformatics methods. Overexpression of miR-7 in CAFs led to down-regulation of RASSF2, which dramatically decreased the secretion of PAR-4 from CAFs and then enhanced the proliferation and migration of the co-cultured cancer cells. PMID: 27901488
7. The miR-7 can inhibit the activation of ERK/MAPK signaling pathway by down-regulating FAK expression, thereby suppressing the proliferation, migration and invasion of NSCLC cells. The miR-7 and its target gene FAK may be novel targets for the diagnosis and treatment of NSCLC. PMID: 27764812
8. Serum miR-7 was significantly elevated in the T2DM patients [(401.0+/-34.37) fmol/L, P<0.001] and in the T2DMC patients [(501.4+/-81.69) fmol/L, P<0.001] when compared with the controls [(175.7+/-16.59) fmol/L]. PMID: 28646700
9. LILRB1 is used for immune evasion by Plasmodium falciparum by associating with RIFINs. PMID: 29186116
10. Data indicate the MHC class I-LILRB1 signaling axis as an important regulator of the effector function of innate immune cells. PMID: 29180808
11. RT-PCR analysis of serum samples confirmed that miR-7-5p and miR-26b-5p were upregulated in the serum of left ventricular hypertrophy hypertensive patients compared with healthy subjects. Our findings suggest that these miRNAs may play a role in the pathogenesis of hypertensive left ventricular hypertrophy and may represent novel biomarkers for this disease. PMID: 29069223
12. LILRB1 ligation during the differentiation of monocytes to dendritic cells in vitro results in increased ABIN1 expression. ABIN1 mediates the effects of LILRB1 ligation-induced inhibitory effects on immune responses. PMID: 27129285
13. the results support that a regulated assembly of these noncanonical HLA-I conformers during the immune response may enhance the avidity of their interaction with LILRB1. PMID: 27109306
14. miR7 negatively regulates PAK1 protein expression but has no effect on PAK1 mRNA expression. Knockdown of PAK1 expression markedly suppressed thyroid cancer cell proliferation, migration and invasion. PMID: 27430434
15. this study shows that in the tuberculosis with pleural effusion -PE cases, ILT-2 expressing cells are reduced at the local disease site PMID: 26776460
16. this study shows that elevated levels of plasmatic sILT2 are present in non-muscle-infiltrating bladder cancer patients PMID: 26874236
17. a woman's heterozygosity in HLA-G and LILRB1 might be an advantage for a success of reproduction, but the partner's heterozygosity in 9A/10A KIR2DL4 alleles might not PMID: 26973020
18. Surprisingly, the ability of LIR1(+) natural killer cells to control virus spread differed between human cytomegalovirus strains, and this phenomenon was dependent on amino acid sequences within the viral ligand UL18. PMID: 26739048
19. LIR-1 expression on CD8+ T cells in Rheumatoid Arthritis patients was higher than that in healthy controls. PMID: 26314621
20. One SNP in LILRB1 (5724G>A) influenced the risk of NSCLC. 5724G>A was associated with protection from tumor cell infiltration of regional lymph nodes. Expression in tumor tissue correlated with tumor stage. PMID: 25855135
21. Our findings offer new insights into the immunopathology of rheumatoid arthritis(RA) patients with long-lasting anti-RA-treatment and highlight the importance to also measure the binding capability of sHLA-G to LILRB1 PMID: 25853899
22. Increased frequency of ILT2-expressing CD56(dim)CD16(+) NK cells correlates with disease severity of pulmonary tuberculosis. PMID: 24909369
23. MiR-7, inhibited indirectly by lincRNA HOTAIR, directly inhibits SETDB1 and reverses the Epithelial-mesenchymal transition of breast cancer stem cells by down regulating the STAT3 pathway PMID: 25070049
24. Patients expressing high levels of CD85j had an impaired ability to lyse triple negative breast cancer cells in the presence of Cetuximab. We also found that CD85j overexpression was associated with HLA-I and soluble HLA-G expression by tumors. PMID: 25726929
25. Binding of specific AP-1 factors, we found JunD associated with the LILRB1 distal promoter. PMID: 24038602
26. These data show that S100A9 protein, through ligation with CD85j, can stimulate the anti-HIV-1 activity of NK cells. PMID: 24156302
27. To escape antiviral response, antibody-opsonized dengue virus coligates LILRB1 to inhibit FcgammaR signaling for type-I IFN-stimulated gene expression. PMID: 24550301
28. This B cell regulatory mechanism involving ILT2-HLA-G interaction brings important insight to design future B cell-targeted therapies aimed at reducing inappropriate immune reaction in allotransplantation and autoimmune diseases. PMID: 24453251
29. these results suggest that ILT2 participates in the defective immune-regulation observed in patients with systemic lupus erythematosus. PMID: 23756160
30. MiR-7 is a novel miRNA with tumor suppressive function in colon cancer by targeting oncogenic YY1. PMID: 23208495
31. HLA-G5 could be responsible, at least in part, via its interaction with ILT2, for decidual T cell IL-4 production, known to be crucial for successful pregnancy. PMID: 23997222
32. miR-7 efficiently silenced some genes involved in the epidermal growth factor receptor (EGFR) pathway and achieved favorable effects in treating glioma in vivo and in vitro PMID: 23404538
33. Cis association of leukocyte Ig-like receptor 1 with MHC class I modulates accessibility to antibodies and HCMV UL18. PMID: 23348966
34. study concludes LIR-1 alone does not directly influence NK-cell-mediated cytotoxicity against multiple myeloma (MM); work provides investigation of inhibitory capability of LIR-1 in NK-92-mediated cytotoxicity against MM and the functional evaluation of LIR-1 on MM and LBCL lymphoblastoid cell line PMID: 22844324
35. A significant correlation was identified between miR-7 expression and tumor grade in high-risk ER+ breast cancer. PMID: 22623953
36. expression of CTLA-4 and LIR-1 by peripheral T. cruzi antigen-responsive IFN-gamma-producing and total T cells from chronically T. cruzi-infected subjects with different clinical forms of the disease PMID: 22574131
37. The carriage of the HLA-G minus 14-bp polymorphism, LILRB1 single nucleotide polymorphism rs1061680, and activating and inhibitory KIRs are different in different ethnic groups but generally is not correlated with susceptibility to HIV-1. PMID: 22296096
38. The expression of CD85j, NKG2D, NKp30, NKp44, KIR2DL1/S1 and KIR2DL2/L3/S2 receptors at the cell surface evolves between 8 and 12 weeks of gestation. PMID: 22242197
39. [review] This review of LILR during HIV-1 infection focuses on the dynamic interplay between LILR and HLA class I molecules in determining HIV-1 disease progression, and the effects of HIV-1 mutational escape on LILR-mediated immune recognition. PMID: 22028331
40. Association of overt and subclinical atherosclerotic disease with LILRB1+ NK and T-cells reflects a relationship between the immune challenge by infections and cardiovascular disease risk, without attributing a dominant role for human cytomegalovirus. PMID: 21817101
41. The rate of HLA-G receptor ILT-2 on CD4(+)T cell, CD8(+)T cell and B cell in acute rejection group was statistically lower than that in stable kidney function group after renal transplantation. PMID: 21092455
42. The abnormal expression and function of ILT2 detected in autoimmune thyroid disease suggests that this receptor may participate in the pathogenesis of this condition. PMID: 21551166
43. High affinity soluble ILT2 receptor is a potent inhibitor of CD8(+) T cell activation. PMID: 21213105
44. show that mAb 256 does not target a TCR ligand but blocks key interactions between non-TCR molecules on effector gammadelta T cells and ILT2 molecule, expressed by tumor targets PMID: 21233315
45. LILRB1 exhibits a lower binding affinity for a subset of HLA-A alleles expressed by myeloid cells. PMID: 21270408
46. T cells require ILT2-positive cells to upregulate cell-surface ILT2 upon activation, evidence that sensitivity to modulatory molecules can be acquired from other cells. PMID: 21242521
47. level of expression on NK cells varies depending on genetic polymorphism PMID: 20600445
48. the proportions of CD8+ T cells displaying LILRB1, an inhibitory NKR expressed at late stages of T cell differentiation, were directly related with age and MS duration PMID: 20580616
49. Blockade of LILRB1 and LILRB3 receptors by monoclonal antibodies or short interfering RNA (siRNA) abrogated the specific antigen-presenting properties of dendritic cells, implying an important regulatory role of these molecules. PMID: 20631139
50. alloreactivity of a significant fraction of KIR(-) NK cells leads to killing of acute myelogenous leukemia and acute lymphoblastic leukemia blasts that is mediated by NKG2A and LIR-1. PMID: 20139023
顯示更多

收起更多
亞細胞定位：

Cell membrane; Single-pass type I membrane protein.; [Isoform 5]: Secreted.
組織特異性：

Expressed in B cells, monocytes and various dendritic cell (DC) subsets including myeloid, plasmacytoid and tolerogenic DCs (at protein level). Expressed in decidual macrophages (at protein level). Expressed in decidual NK cells (at protein level).
數(shù)據(jù)庫鏈接：

HGNC: 6605

OMIM: 604811

KEGG: hsa:10859

STRING: 9606.ENSP00000315997

UniGene: Hs.667388

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human